Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical...

The drug makers Merck and Moderna announced on Thursday the full results of a closely watched trial of an experimental vaccine given to patients with melanoma.